Ingelheim, Germany / Ridgefield, Connecticut, U.S. Data from the Phase Ib Beamion LUNG-1 trial evaluating zongertinib in treatment-naive patients with advanced HER2 (ERBB2)-mutant NSCLC were presented for the first time at ESMO 2025. Confirmed response by blinded independent central review was 77%, with 96% of patients achieving disease control.1 Zongertinib recently received Breakthrough Therapy Designations […]

Boehringer's zongertinib demonstrated a 77% objective response rate in treatment-naive patients with advanced HER2 (ERBB2)-mutant NSCLC GlobeNewswire October 17, 2025 Ingelheim, Germany / Ridgefield, Connecticut, U.S. Data from the Phase Ib Beamion LUNG-1 trial evaluating zongertinib in treatment-naive patients with advanced HER2 (ERBB2)-mutant NSCLC were presented for the first time at ESMO 2025. Confirmed response

NEW YORK CITY, NY / ACCESS Newswire / October 17, 2025 / Pomerantz LLP is investigating claims on behalf of investors of EHang Holdings Limited ("EHang" or the "Company") (NASDAQ:EH). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980. The investigation concerns whether EHang and certain of its officers and/or

NEW YORK, NY, NY / ACCESS Newswire / October 17, 2025 / Pomerantz LLP is investigating claims on behalf of investors of Trinseo PLC ("Trinseo" or the "Company") (NYSE:TSE). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980. The investigation concerns whether Trinseo and certain of its officers and/or directors

NEW YORK CITY, NY / ACCESS Newswire / October 17, 2025 / Pomerantz LLP is investigating claims on behalf of investors of Organogenesis Holdings Inc.("Organogenesis" or the "Company") (NASDAQ:ORGO). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980. The investigation concerns whether Organogenesis and certain of its officers and/or directors

Altamirano PLLC Issues Notice to Inspired Healthcare Capital (IHC) Investors on Recovery Options GlobeNewswire October 17, 2025 NEW YORK, Oct. 17, 2025 (GLOBE NEWSWIRE) — Altamirano PLLC, a New York-based securities arbitration law firm, has announced an investigation into the brokerage firms that sold Inspired Healthcare Capital (IHC) investments. IHC, an Arizona-based alternative investment sponsor,

NEW YORK CITY, NY / ACCESS Newswire / October 17, 2025 / Pomerantz LLP is investigating claims on behalf of investors of Matrix Service Company ("Matrix" or the "Company") (NASDAQ:MTRX). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980. The investigation concerns whether Matrix and certain of its officers and/or

NEW YORK CITY, NY / ACCESS Newswire / October 17, 2025 / Pomerantz LLP is investigating claims on behalf of investors of Brunello Cucinelli S.p.A. ("Brunello Cucinelli" or the "Company") (OTCMKTS:BCUCY). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980. The investigation concerns whether Brunello Cucinelli and certain of its

NEW YORK CITY, NY / ACCESS Newswire / October 17, 2025 / Pomerantz LLP is investigating claims on behalf of investors of Roblox Corporation ("Roblox" or the "Company") (NYSE:RBLX). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980. The investigation concerns whether Roblox and certain of its officers and/or directors

NEW YORK CITY, NY / ACCESS Newswire / October 17, 2025 / Pomerantz LLP announces that a class action lawsuit has been filed against Fly-E Group, Inc. ("Fly-E" or the "Company") (NASDAQ:FLYE). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, (or 888.4-POMLAW), toll-free, Ext. 7980. Those who inquire by e-mail are